Banco Bilbao Vizcaya Argentaria S.A. Lowers Holdings in Novo Nordisk A/S $NVO

Banco Bilbao Vizcaya Argentaria S.A. decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 10.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 100,215 shares of the company’s stock after selling 11,808 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Novo Nordisk A/S were worth $6,915,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of NVO. Stone House Investment Management LLC purchased a new stake in Novo Nordisk A/S in the 1st quarter valued at about $30,000. NewSquare Capital LLC boosted its stake in Novo Nordisk A/S by 174.1% during the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after buying an additional 282 shares during the period. Disciplina Capital Management LLC increased its position in shares of Novo Nordisk A/S by 162.3% during the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock valued at $33,000 after acquiring an additional 297 shares during the last quarter. Dagco Inc. purchased a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at approximately $35,000. Finally, Mid American Wealth Advisory Group Inc. acquired a new position in shares of Novo Nordisk A/S in the 2nd quarter worth approximately $37,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 1.9%

NVO opened at $48.22 on Friday. The business has a fifty day moving average price of $54.55 and a 200 day moving average price of $61.01. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. Novo Nordisk A/S has a 12 month low of $45.05 and a 12 month high of $112.52. The stock has a market capitalization of $215.32 billion, a price-to-earnings ratio of 13.25, a PEG ratio of 2.33 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The business had revenue of $11.74 billion during the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S has set its FY 2025 guidance at EPS. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on NVO. Jefferies Financial Group initiated coverage on shares of Novo Nordisk A/S in a report on Monday, October 27th. They issued an “underperform” rating for the company. Rothschild & Co Redburn raised Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 16th. Rothschild Redb upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 16th. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Finally, TD Cowen dropped their target price on Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating for the company in a research report on Tuesday, August 19th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $59.20.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.